Gibble, Theresa Hunter
Naegeli, April N.
Grabner, Michael
Isenberg, Keith
Shan, Mingyang
Teng, Chia-Chen
Curtis, Jeffrey R.
Funding for this research was provided by:
This study was funded by Eli Lilly and Company.
Article History
Received: 3 March 2022
Accepted: 13 February 2023
First Online: 9 March 2023
Declarations
:
: Researchers’ access to claims data was limited to data stripped of identifiers to ensure confidentiality. HealthCore maintains data use agreements with the covered entities in compliance with the Health Insurance Portability and Accountability Act. An Institutional Review Board did not review the study since only this limited data set was accessed. The study was conducted under the research provisions of Privacy Rule 45 CFR 164.514(e). The study used data that was previously collected and did not impose any form of intervention; the data was deidentified to protect subject privacy. Therefore, a formal consent was not required. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices as well as legal and regulatory requirements. The HealthCore database is a proprietary health claims database and is not accessible to the public. HealthCore researchers were provided access pursuant to Health Insurance Portability and Accountability Act. Further information concerning access to HealthCore’s database may be provided upon request.
: Not applicable.
: JRC reported financial relationships with AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB. KI is an Anthem Inc. employee and shareholder. MG and CCT are employees of HealthCore, Inc., which was under contract with Eli Lilly and Company for the conduct of the study on which this manuscript is based. MG is a shareholder of Anthem Inc. THG, AN, and MS are employees and shareholders of Eli Lilly and Company, Indiana, Indianapolis, US.